title: A novel recombinant protein of ephrinA1-PE38/GM-CSF activate dendritic cells vaccine in rats with glioma.
abstract: Dendritic cells loaded with tumor-associated antigens can effectively stimulate the antitumor immune response of cytotoxic T lymphocytes in the body, which facilitates the development of novel and effective treatments for cancer. In this study, the adenovirus-mediated ephrinA1-PE38/GM-CSF was successfully constructed using the overlap extension method, and verified with sequencing analysis. HEK293 cells were infected with the adenovirus and the cellular expression of ephrinA1-PE38/GM-CSF was measured with an enzyme-linked immunosorbent assay. The recombinant adenovirus was then delivered into the tumor-bearing rats and the results showed that such treatment significantly reduced the volumes of gliomas and improved the survival of the transplanted rats. The results from immunohistochemistry and flow cytometry suggested that this immunomodulatory agent cause activation of dendritic cells. The findings that ephrinA1-PE38/GM-CSF had a high efficacy in the activation of the dendritic cells would facilitate the development of in vivo dendritic-cell vaccines for the treatment of gliomas in rats. Our new method of DC vaccine production induces not only a specific local antitumor immune response but also a systemic immunotherapeutic effect. In addition, this method completely circumvents the risk of contamination related to the in vitro culture of DCs, thus greatly improving the safety and feasibility of clinical application of the DC vaccines in glioma.
authors: Department of Neurosurgery, Zhengzhou University People's Hospital, 7 Weiwu Road, Zhengzhou City, Henan Province, 450003, People's Republic of China.
authors: Ming
authors: M
authors: Li
authors: Bin
authors: B
authors: Wang
authors: Zhonghua
authors: Z
authors: Wu
authors: Jiadong
authors: J
authors: Zhang
authors: Xiwen
authors: X
authors: Shi
authors: Wenlan
authors: W
authors: Cheng
authors: Shuangyin
authors: S
authors: Han
mesh_terms: D036002:ADP Ribose Transferases / Q000235:genetics / Q000276:immunology*; D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D001427:Bacterial Toxins / Q000235:genetics / Q000276:immunology*; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology; D036382:Ephrin-A1 / Q000235:genetics / Q000276:immunology*; D005098:Exotoxins / Q000235:genetics / Q000276:immunology*; D005910:Glioma / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics / Q000276:immunology*; D057809:HEK293 Cells; D006801:Humans; D007111:Immunity, Cellular / Q000235:genetics / Q000276:immunology; D056747:Immunomodulation; D051381:Rats; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D037521:Virulence Factors / Q000235:genetics / Q000276:immunology*; D000097668:Pseudomonas aeruginosa Exotoxin A
chemical_list: D036002:ADP Ribose Transferases; D000951:Antigens, Neoplasm; D001427:Bacterial Toxins; D019496:Cancer Vaccines; D036382:Ephrin-A1; D005098:Exotoxins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D011994:Recombinant Proteins; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A